Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553051 | 1.00 | NFE2L2 (0.67) | NFE2L2RELASNCAMAPTRECQL | |
| SCHEMBL10459190 | 0.87 | HDAC1 (0.55) | SNCAHDAC1TTRSLC16A3ALDH1A1 | |
| SCHEMBL10459191 | 0.87 | HDAC1 (0.55) | SNCAHDAC1TTRSLC16A3ALDH1A1 | |
| SCHEMBL22553033 | 0.81 | NFE2L2 (0.55) | NFE2L2HDAC1TTR | |
| SCHEMBL7552105 | 0.81 | ALDH1A1 (0.63) | NFE2L2TTRALDH1A1 | |
| SCHEMBL3292441 | 0.81 | NFE2L2 (1.00) | NFE2L2RELA | |
| SCHEMBL3292445 | 0.81 | NFE2L2 (1.00) | NFE2L2RELA | |
| SCHEMBL11545296 | 0.81 | HDAC1 (0.67) | MAPTRECQLHDAC1TTRMAOB | |
| SCHEMBL1927729 | 0.81 | HDAC1 (0.67) | MAPTRECQLHDAC1TTRMAOB | |
| SCHEMBL14401252 | 0.81 | NFE2L2 (1.00) | NFE2L2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961178-B2 | Cycloaddition reactions using quantum dots | NORTHWESTERN UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961178-B2 | Cycloaddition reactions using quantum dots | NORTHWESTERN UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200331836-A1 | CYCLOADDITION REACTIONS USING QUANTUM DOTS | NORTHWESTERN UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-20200331836-A1 | CYCLOADDITION REACTIONS USING QUANTUM DOTS | NORTHWESTERN UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331836-A1 | CYCLOADDITION REACTIONS USING QUANTUM DOTS | SYNGR2, SYNJ1, SQLE | NFE2L2 882/4885RELA 1610/4885SNCA 16/4885 |
| US-10961178-B2 | Cycloaddition reactions using quantum dots | SYNGR2, SYNJ1, SQLE | NFE2L2 882/4885RELA 1610/4885SNCA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.